(Q36953155)

17 August 2017

1 reference

title

Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome (English)

1 reference

hereditary breast ovarian cancer

17 August 2017

1 reference

1 reference

Dimitrios H Roukos

1

1 reference

17 August 2017

Evangelos Briasoulis

series ordinal

2

1 reference

17 August 2017

publication date

1 October 2007

1 reference

Nature Clinical Practice Oncology

17 August 2017

published in

1 reference

17 August 2017

volume

4

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

578-590

1 reference

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Identification of the breast cancer susceptibility gene BRCA2

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

BRCA1 and BRCA2: 1994 and beyond

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Cancer susceptibility and the functions of BRCA1 and BRCA2

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Prevention and management of hereditary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Breast cancer genetics: what we know and what we need

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Polygenic susceptibility to breast cancer and implications for prevention

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying theCHEK2*1100delCGermline Mutation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Increased risk of breast cancer associated with CHEK2*1100delC

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Genes on the Web--direct-to-consumer marketing of genetic testing

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

DNA Testing, Banking, and Genetic Privacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Clinical Characteristics Affect the Impact of an Uninformative DNA Test Result: The Course of Worry and Distress Experienced by Women Who Apply for Genetic Testing for Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Guidelines for the management of women at increased familial risk of breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Assessing BRCA carrier probabilities in extended families.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

CANCER: Enhanced: A Risky Business--Assessing Breast Cancer Risk

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Role of surgery in the prophylaxis of hereditary cancer syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Surgical management of BRCA1 and BRCA2 carriers: bitter choices slightly sweetened

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up ofBRCA1Mutation Carriers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Modifiers of risk of hereditary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Evidence-based management options for women at increased breast/ovarian cancer risk

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

American Cancer Society guidelines for breast cancer screening: update 2003.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

The development of interval breast malignancies in patients with BRCA mutations.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0930

1 reference

7 January 2021

Biology of epithelial ovarian cancer: implications for screening women at high genetic risk

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Overview of the main outcomes in breast-cancer prevention trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Prevention of hormone-related cancers: breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Recent results from clinical trials using SERMs to reduce the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

SERMs: meeting the promise of multifunctional medicines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Prevention strategies with aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Chemoprevention of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Bone safety of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Aromatase inhibitors and bone health in women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Aromatase inhibitors in breast cancer: an overview

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Endometrial cancer and hormone-replacement therapy in the Million Women Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

No news is (not necessarily) good news: impact of preliminary results for BRCA1 mutation searches

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy inBRCA1/2-Associated Stage I/II Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Improved survival in women with BRCA-associated ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Treating cancer by targeting a weakness

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Efficient Deletion of NormalBrca2-Deficient Intestinal Epithelium by Poly(ADP-Ribose) Polymerase Inhibition Models Potential Prophylactic Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Inhibition of poly(ADP-ribose) polymerase in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Basal-like breast cancer and the BRCA1 phenotype

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Triple-negative breast cancer: therapeutic options

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0930

7 January 2021

Identifiers

DOI

10.1038/NCPONC0930

1 reference

17 August 2017

1 reference